Alphabet’s Isomorphic Labs in Funding Talks for at Least $40 Billion Value
THE SO WHAT
A $40B valuation for an AI-native drug discovery shop makes clear that pharma plus models is being priced as its own category, not just a tool vendor. Biotech and pharma operators should assume that access to proprietary model pipelines and data-sharing partnerships becomes a strategic weapon, not a back-office efficiency play.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureExclusive: Weight loss startup Yazen raises €50m led by Verdane
Consumer health is still one of the few categories where narrative plus outcomes can justify late-stage checks. If you’re building in digital health, assume investors will demand either clear reimbursement pathways or subscription economics that look more like SaaS than coaching.
Startups & VentureBending Spoons CEO on why M&A fails
The failure mode in most acquihires and rollups is integration discipline, not deal logic. If you’re buying product or talent this cycle, over-allocate leadership time to post-close operating cadence and under-allocate to pre-close pitch theater.
Startups & VentureWhy Investors Are Skeptical Over Australian Data Center Company Firmus's IPO
A polarizing IPO for an Nvidia-backed data center builder shows public markets are starting to separate “AI infra beta” from real contracted demand. If you’re raising for infra-heavy AI plays, expect sharper questions on utilization, power contracts, and tenant concentration — not just logo slides and Nvidia proximity.
Startups & VentureMalaysian Chip Firm SQAI Said to Plan $73 Million IPO in Early 2027
A RM300M (~$73M) IPO for a Malaysian advanced interconnect player is another data point that packaging and back-end are where smaller regional firms can still list and grow. If you're capacity-constrained on advanced packaging, start mapping Southeast Asian suppliers now—access may tighten post-IPO.